NCT02149524View on ClinicalTrials.gov

A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

875

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

February 28, 2017

Conditions
HER2 Positive Early or Locally Advanced Breast Cancer
Interventions
DRUG

Herceptin (trastuzuamb)

Intravenous administration

DRUG

SB3 (proposed trastuzumab biosimilar)

Intravenous administration

Trial Locations (1)

Unknown

Investigational Site, Prague

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02149524 - A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter